Erratum

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial (Lancet (2015) 385 (1853-1862))

Craig Moskowitz, A. Nademanee, T. Masszi

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalThe Lancet
Volume386
Issue number9993
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Placebos
Recurrence
Therapeutics
cAC10-vcMMAE

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{f3638aec4b534bc7872cbd4445b73cf4,
title = "Erratum: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial (Lancet (2015) 385 (1853-1862))",
author = "Craig Moskowitz and A. Nademanee and T. Masszi",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/S0140-6736(15)61474-X",
language = "English (US)",
volume = "386",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9993",

}

TY - JOUR

T1 - Erratum

T2 - Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial (Lancet (2015) 385 (1853-1862))

AU - Moskowitz, Craig

AU - Nademanee, A.

AU - Masszi, T.

PY - 2015/1/1

Y1 - 2015/1/1

UR - http://www.scopus.com/inward/record.url?scp=84938879526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938879526&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(15)61474-X

DO - 10.1016/S0140-6736(15)61474-X

M3 - Comment/debate

VL - 386

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9993

ER -